Resmed INC Form 4 insider transactions

ResMed Inc. CEO Michael J. Farrell exercised stock options and subsequently sold 8,009 shares of common stock under a pre-arranged 10b5-1 plan.

ResMed's Chief Financial Officer, Brett Sandercock, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.

ResMed Inc.'s Chief Commercial Officer for SaaS, Kaushik Ghoshal, is no longer subject to Section 16 reporting requirements following his termination effective August 1, 2025.

ResMed's Global General Counsel, Michael J. Rider, sold 50 shares of common stock for $281.90 per share on August 1, 2025, under a pre-arranged 10b5-1 plan.

ResMed CEO Michael Farrell executed a pre-arranged transaction, exercising stock options and simultaneously selling an equal number of shares.

ResMed Inc. Director Peter C. Farrell has filed a Form 4 indicating a future sale of 945 shares of common stock on July 2, 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed's Chief Financial Officer, Brett Sandercock, completed a series of pre-arranged transactions on July 1, 2025, involving the exercise of stock options and the subsequent sale of common stock under a Rule 10b5-1 plan.

ResMed's Global General Counsel, Michael J. Rider, sold 66 shares of common stock for $256.99 per share on July 1, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc. CEO Michael J. Farrell exercised 8,009 stock options and subsequently sold the acquired shares, as reported in a recent SEC Form 4 filing.

ResMed Inc. Director Peter C. Farrell reported the sale of 2,000 shares of common stock for $247.32 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, sold 1,000 shares of common stock for $243.78 per share on June 2, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc.'s Global General Counsel, Michael J. Rider, reported the sale of 41 shares under a Rule 10b5-1 plan and the disposition of 267.244 shares for tax withholding related to RSU vesting on June 2, 2025.

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, sold 3,644 shares of common stock for approximately $891,500 under a pre-established Rule 10b5-1 trading plan.

Director Jan De Witte of ResMed Inc. sold 2,000 shares of company stock at $243.47 per share under a pre-arranged 10b5-1 trading plan.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold a portion of the acquired shares under a pre-arranged Rule 10b5-1 trading plan.

ResMed director Peter Farrell sold 2,000 shares of common stock at $242.25 per share under a pre-arranged 10b5-1 trading plan.

ResMed's Chief Financial Officer, Brett Sandercock, executed a sale of 1,000 shares of ResMed common stock at a price of $215.58 per share on April 8, 2025, under a pre-arranged 10b5-1 trading plan.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock on April 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of common stock at a price of $219.74 per share under a pre-arranged 10b5-1 trading plan.

Michael J. Rider, Global General Counsel of ResMed Inc., reports the sale of 64 shares of ResMed common stock at a price of $222.86 per share on April 1, 2025.

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed common stock at a price of $230.36 per share on March 10, 2025, under a pre-arranged 10b5-1 trading plan.

Chief Commercial Officer of ResMed, Kaushik Ghoshal, exercised stock options and sold shares of ResMed common stock under a pre-arranged 10b5-1 trading plan.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold a portion of the acquired shares on March 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Peter Farrell, a director at ResMed Inc., sold 2,000 shares of common stock at a price of $227.71 per share on March 5, 2025, under a pre-arranged 10b5-1 trading plan.

Kaushik Ghoshal, Chief Commercial Officer, SaaS at ResMed, executed stock options and sold shares on March 3, 2025, under a pre-arranged 10b5-1 trading plan.

Michael J. Rider, Global General Counsel of ResMed Inc., sold 64 shares of common stock at $234.1 per share on March 3, 2025, under a pre-arranged 10b5-1 trading plan.

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed common stock at a price of $238.98 per share on February 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold a portion of the acquired shares under a pre-arranged Rule 10b5-1 trading plan.

Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of common stock at a price of $242.11 per share on February 5, 2025, under a pre-arranged 10b5-1 trading plan.

Michael J. Rider, Global General Counsel of ResMed Inc., sold 64 shares of common stock at $242.42 per share on February 3, 2025, under a pre-arranged 10b5-1 trading plan.